Iptacopan: all 27 studies that test it

Page 1 of 1. Open to participants first (11), then studies with results posted, then the rest; newest registration first within each.

• Safety and Efficacy of Iptacopan in Patients With High-Risk Transplantation-Associated Thrombotic MicroangiopathyRecruitingNCT07347990Not applicable
• Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANRecruitingNCT06994845Phase 3
• Study to Assess the Pharmacokinetics, Safety, and Tolerability of Iptacopan in Pediatric PNH PatientsRecruitingNCT06934967Phase 3
• A Multicenter Prospective Study of Iptacopan in the Treatment of Refractory/Relapsed Autoimmune Hemolytic Anemia (AIHA)Not yet recruitingNCT06847607Not applicable
• Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgANRecruitingNCT06797518Phase 2
• Efficacy and Safety of Switching From Anti-C5 Antibody Treatment to Iptacopan Treatment in Study Participants With Atypical Hemolytic Uremic Syndrome (aHUS)RecruitingNCT05935215Phase 3
• Evaluate Long-term Safety, Tolerability and Efficacy of Iptacopan in Study Participants With aHUSRecruitingNCT05795140Phase 3
• Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGNRecruitingNCT05755386Phase 3
• Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.RecruitingNCT04817618Phase 3
• A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA NephropathyRecruitingNCT04557462Phase 3
• Long-term Efficacy, Safety and Tolerability of Iptacopan in C3G or IC-MPGNRecruitingNCT03955445Phase 3
• Single Arm, Open Label Trial With Iptacopan Treatment for 24 Weeks, in Patients on Stable Regimen of Anti-C5 Who Switch to Iptacopan.CompletedNCT05630001Phase 3Results posted
• Basket Study to Assess Efficacy, Safety and PK of Iptacopan (LNP023) in Autoimmune Benign Hematological DisordersTerminatedNCT05086744Phase 2Results posted
• Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor TherapyCompletedNCT04820530Phase 3Results posted
• Study of Efficacy and Safety of Twice Daily Oral LNP023 in Adult PNH Patients With Residual Anemia Despite Anti-C5 Antibody TreatmentCompletedNCT04558918Phase 3Results posted
• Efficacy and Safety of LNP023 Compared With Rituximab in Subjects With Idiopathic Membranous NephropathyTerminatedNCT04154787Phase 2Results posted
• Efficacy, Safety, Pharmacokinetics and Pharmacodynamics Study, Assessing Multiple LNP023 Doses in Adult Patients With Paroxysmal Nocturnal HemoglobinuriaCompletedNCT03896152Phase 2Results posted
• Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not TransplantedCompletedNCT03832114Phase 2Results posted
• Study of Safety, Efficacy, Tolerability, Pharmacokinetics and Pharmacodynamics of LNP023 in in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT03439839Phase 2Results posted
• Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by InflammationCompletedNCT03373461Phase 2Results posted
• A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.Active, not recruitingNCT06517758Phase 3
• Iptacopan in Patients With ANCA Associated VasculitisActive, not recruitingNCT06388941Phase 2
• A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular DegenerationActive, not recruitingNCT05230537Phase 2
• Pharmacokinetic (PK) and Safety Study of Iptacopan (LNP023) in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Matched Control Healthy Participants With Normal Hepatic Function.CompletedNCT05078580Phase 1
• Efficacy and Safety of Iptacopan (LNP023) in Adult Patients With Atypical Hemolytic Uremic Syndrome Naive to Complement Inhibitor TherapyCompletedNCT04889430Phase 3
• Long-term Safety and Tolerability of Iptacopan in Patients With Paroxysmal Nocturnal HemoglobinuriaActive, not recruitingNCT04747613Phase 3
• Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy PatientsCompletedNCT04578834Phase 3

← Iptacopan overview